title: Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
abstract: The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, which is randomizing 74,000 screening arm participants (37,000 men, 37,000 women; ages 55-74) and an equal number of nonscreened controls, is a unique setting for the investigation of the etiology of cancer and other diseases and for the evaluation of potential molecular markers of early disease. At entry, baseline information is collected by questionnaire on dietary intake, tobacco and alcohol use, reproductive history (for women), family history of cancer, use of selected drugs, and other selected risk factors. Blood samples collected at the baseline screening exam are aliquoted to serum, plasma, red blood cell, and buffy coat fractions. At the next two annual screening visits, serum samples are collected. At the third annual reexamination, cryopreserved whole blood is obtained, in addition to serum, plasma, red blood cell, and buffy coat fractions. At the fourth and fifth years, serum, plasma, and buffy coat are collected. All blood samples are shipped to a central repository for long-term storage at -70 degrees C. Dietary questionnaires and buccal cells for DNA analysis are obtained from nonscreened controls. Cancer cases are identified through annual follow-up questionnaires, and all deaths are identified through vital status tracing mechanisms. Procedures are being developed to obtain archival pathologic material for selected cases of cancer and related diseases. Initial investigations are focusing on the etiology of colorectal cancer and on the operative characteristics of tests for the early detection of colorectal and prostate cancer.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892-7346, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Hayes
authors.forename: D
authors.initials: D
authors.lastname: Reding
authors.forename: W
authors.initials: W
authors.lastname: Kopp
authors.forename: A F
authors.initials: AF
authors.lastname: Subar
authors.forename: N
authors.initials: N
authors.lastname: Bhat
authors.forename: N
authors.initials: N
authors.lastname: Rothman
authors.forename: N
authors.initials: N
authors.lastname: Caporaso
authors.forename: R G
authors.initials: RG
authors.lastname: Ziegler
authors.forename: C C
authors.initials: CC
authors.lastname: Johnson
authors.forename: J L
authors.initials: JL
authors.lastname: Weissfeld
authors.forename: R N
authors.initials: RN
authors.lastname: Hoover
authors.forename: P
authors.initials: P
authors.lastname: Hartge
authors.forename: C
authors.initials: C
authors.lastname: Palace
authors.forename: J K
authors.initials: JK
authors.lastname: Gohagan
mesh_terms: D000368:Aged; D015415:Biomarkers; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D003625:Data Collection; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000209:etiology* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D015415:Biomarkers